---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000070"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:56:40.722688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus Q3 GAAP net loss $16M; raises FY adjusted op earnings guide to $95-110M

## Summary
- Total revenues $153.9M; Qelbree net sales $37.1M (+103% YoY), GOCOVRI $32.9M (+18% YoY).
- GAAP net loss of $16.0M ($0.29 diluted EPS); adjusted operating earnings $37.3M, up 47% YoY.
- FY 2023 adjusted operating earnings guidance raised to $95-110M from $75-100M; total revenue guidance $590-610M.
- FDA accepted SPN-830 NDA resubmission for Parkinson's; PDUFA date April 5, 2024.
- Qelbree IQVIA prescriptions 163,344 (+73% YoY); prescriber base expanded to ~24,189.

## SEC filing metadata
- accession: 0001356576-23-000070
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/0001356576-23-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/supn-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000070
- JSON: https://secwatch.observer/filing/0001356576-23-000070.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000070.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. updated its the third quarter ended September 30, 2023 guidance (raised).
  - Period: the third quarter ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On November 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/0001356576-23-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.